CL2020000127A1 - Therapeutic modulators of the reverse mode of atp synthase. - Google Patents
Therapeutic modulators of the reverse mode of atp synthase.Info
- Publication number
- CL2020000127A1 CL2020000127A1 CL2020000127A CL2020000127A CL2020000127A1 CL 2020000127 A1 CL2020000127 A1 CL 2020000127A1 CL 2020000127 A CL2020000127 A CL 2020000127A CL 2020000127 A CL2020000127 A CL 2020000127A CL 2020000127 A1 CL2020000127 A1 CL 2020000127A1
- Authority
- CL
- Chile
- Prior art keywords
- atp synthase
- reverse mode
- therapeutic modulators
- atp
- modulators
- Prior art date
Links
Abstract
LOS COMPUESTOS DE LA SIGUIENTE FÓRMULA (I) RALENTIZAN EL MODO DE HIDROLIZACIÓN DE ATP DE LA ATP SINTASA Y SON ÚTILES PARA TRATAR DIVERSAS ENFERMEDADES Y TRASTORNOS, INCLUIDO EL CÁNCER, PARTICULARMENTE LOS CÁNCERES QUE UTILIZAN EL EFECTO WARBURG.THE COMPOUNDS IN THE FOLLOWING FORMULA (I) SLOW THE ATP HYDROLYZATION MODE OF ATP SYNTHASE AND ARE USEFUL TO TREAT VARIOUS DISEASES AND DISORDERS, INCLUDING CANCER, PARTICULARLY THE CANCURS USED BY WARB EFFECT.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1711250.9A GB201711250D0 (en) | 2017-07-13 | 2017-07-13 | Cancer therapy |
PCT/EP2018/051127 WO2018134265A1 (en) | 2017-01-17 | 2018-01-17 | Therapeutic inhibitors of the reverse mode of atp synthase |
GBGB1806421.2A GB201806421D0 (en) | 2018-04-19 | 2018-04-19 | Disclosure |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2020000127A1 true CL2020000127A1 (en) | 2020-04-24 |
Family
ID=70457154
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2020000127A CL2020000127A1 (en) | 2017-07-13 | 2020-01-16 | Therapeutic modulators of the reverse mode of atp synthase. |
Country Status (1)
Country | Link |
---|---|
CL (1) | CL2020000127A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11649238B2 (en) | 2018-01-17 | 2023-05-16 | Glaxosmithkline Intellectual Property Development Limited | Substituted pyrazolo[1,5-a]pyrimidines as PI4K inhibitors |
US11957673B2 (en) | 2017-09-07 | 2024-04-16 | Augusta University Research Institute, Inc. | Specific AKT3 activator and uses thereof |
-
2020
- 2020-01-16 CL CL2020000127A patent/CL2020000127A1/en unknown
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11957673B2 (en) | 2017-09-07 | 2024-04-16 | Augusta University Research Institute, Inc. | Specific AKT3 activator and uses thereof |
US11649238B2 (en) | 2018-01-17 | 2023-05-16 | Glaxosmithkline Intellectual Property Development Limited | Substituted pyrazolo[1,5-a]pyrimidines as PI4K inhibitors |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP20020410A (en) | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES OF THE SAME | |
CL2018001685A1 (en) | Heterocyclic compounds as immuno modulators. | |
CO2019007863A2 (en) | Benzooxazole derivatives as immunomodulators | |
CL2019001709A1 (en) | Pyrazole derivatives as malt1 inhibitors. | |
EA201990665A1 (en) | HPK1 REGULATORS BASED ON PYRAZOLOPYRIDINE DERIVATIVES AND THEIR APPLICATION FOR TREATMENT OF CANCER | |
ECSP20033467A (en) | MACROCYCLIC COMPOUNDS TO TREAT DISEASES | |
PE20191474A1 (en) | AMINO-TRIAZOLOPYRIDINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER | |
BR112017024384A2 (en) | bacteria modified to reduce hyperphenylalaninemia | |
CL2016001082A1 (en) | Process for the synthesis of an indolamine 2,3-dioxygenase inhibitor | |
CL2020001797A1 (en) | Compounds, compositions and methods for treating diseases involving tissues with acidic or hypoxic diseases. | |
CL2017000290A1 (en) | Protein kinase c inhibitors and methods of their use. | |
CO2020002961A2 (en) | Pyruvate kinase activators for use in the treatment of blood disorders | |
GT201400222A (en) | AGENTS TO TREAT DISORDERS THAT INVOLVE THE MODULATION OF RIANODINE RECEPTORS | |
CO2020001107A2 (en) | Therapeutic modulators of the reverse mode of atp synthase | |
UY37466A (en) | N-HYDROXIAMIDINHETEROCICLES SUBSTITUTED AS MODULATORS OF INDOLAMINE 2,3-DIOXYGENASE | |
DOP2016000308A (en) | COMPOUNDS OF 1, 3, 4-TIADIAZOL AND USE OF THE SAME FOR THE TREATMENT OF CANCER | |
NI202000029A (en) | SUBSTITUTED IMIDAZOPYRIDINE AMIDES AND THEIR USE | |
CO2017000552A2 (en) | Biphenyl amides with modified ether groups as hsp90 inhibitors and hsp70 inducers | |
EA201791814A1 (en) | IMIDAZOLYL TRYCYCLIC ENONS AS ANTIOXIDANT INFLAMMATION MODULATORS | |
CL2020000127A1 (en) | Therapeutic modulators of the reverse mode of atp synthase. | |
CL2019002480A1 (en) | Pyrazole derivatives as bromodomain inhibitors. | |
CL2020000586A1 (en) | Modulators of enac expression. | |
PE20181450A1 (en) | 1,3,4-THADIAZOLE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER | |
CL2022003206A1 (en) | Quinolone-derived compounds and their use for the treatment of cancer (div. sol. 202102501) | |
NI201500172A (en) | PHARMACEUTICAL COMPOSITIONS |